TSS
JSPR icon

Two Sigma Securities’s Jasper Therapeutics JSPR Stock Holding History

Two Sigma Securities’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,683
Closed -$32K – 2867
2022
Q2 		$32K Buy
+1,683
New +$47.9K ﹤0.01% 1895

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
FIM
Fernwood Investment Management Quincy, Massachusetts $288M AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Securities's JSPR Position: Q3 2022 in Review

Two Sigma Securities sold out of Jasper Therapeutics (JSPR) in Q3 2022, closing a stake of 1,683 shares — an estimated $32K sold.

Two Sigma Securities first reported a position in JSPR in Q2 2022 and held it in 1 quarter. The position peaked at $32K in Q2 2022. 23 funds tracked by Wall St. Rank hold JSPR as of Q3 2022.

  • Two Sigma Securities reported no remaining Jasper Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Securities sold 1,683 Jasper Therapeutics shares in Q3 2022, an estimated $32K.
  • Two Sigma Securities first reported a position in Jasper Therapeutics in Q2 2022 and held it in 1 quarter.
  • Two Sigma Securities's Jasper Therapeutics position peaked at $32K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2022.

Based on Two Sigma Securities's 13F filing for Q3 2022, filed 14 Nov 2022.